News | August 29, 2014

Brain Sodium Channels in Heart Linked to Sudden Cardiac Death

DNA, sudden cardiac death
August 29, 2014 – A research study published in the July issue Journal of the American College of Cardiology reports that genetic mutations in a neuronal sodium channel gene are associated with inherited sudden cardiac death syndromes, including the Brugada syndrome. The study, performed at the Cardiac Research Institute at Masonic Medical Research Laboratory (MMRL) in Utica, NY, included physicians and scientists from throughout the world who referred patients with life-threatening cardiac arrhythmias to the MMRL for genetic screening. 
 
The Brugada syndrome is associated with an inherited irregular heart rhythm. In some cases the first warning sign is sudden cardiac death. The syndrome affects approximately 5 in 10,000 individuals. The MMRL, one of the top genetic screening centers in the world devoted to inherited sudden cardiac death syndromes, identified the majority of genes responsible for the Brugada syndrome. The MMRL works with families who have tragically lost someone to this insidious disease, testing children, siblings and other relatives to see if they are also at risk. 
 
Prior to this discovery, a genetic defect could be identified in only 35% of Brugada syndrome patients. The new gene associated with the syndrome, called SCN10A, accounts for an additional 17 percent, thus greatly improving our ability to identify a susceptibility gene to over 50 percent of affected index patients. SCN10A encodes a sodium channel previously thought to be associated exclusively with the brain and nervous system. This and other recent studies suggest that it is also present in the heart and when defective can result in life-threatening heart rhythm disorders. 
 
Dr. Dan Hu, the lead author on this study, said these findings provide important insights into the pathophysiology of these syndromes as well as new targets for therapy. Dr. Charles Antzelevitch, Executive Director and Director of research of the MMRL, and senior author of the study added, “The identification of SCN10A as a major susceptibility gene for Brugada syndrome greatly enhances our ability to identify patients and family members who are at risk. These findings also open the door to delineation of the role of other presumably neuronal sodium channels in the electrical function of the heart in both health and disease.” 
 
Although a susceptibility gene can now be identified in over 50 percent of affected index patients, in nearly 50 percent the culprit gene remains unknown. “A negative study does not mean you don’t have the disease; it just means that the genetic marker cannot be identified,” said Antzelevitch. He added that “a great deal of research remains to be done to identify the other genes involved.” 
 
For more information: http://content.onlinejacc.org/issues.aspx

Related Content

AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG| August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Philips released a new version of its iFR system that displays FFR readings as an overlay on live angiographic, angiogram images.

Philips released a new version of its iFR system that displays hemodynamic pressure drop points in an overlay on live angiographic images, matching up the iFR readings with corresponding lesions. The system is supposed to speed diagnostic decision making and help guide percutaneous revascularization procedures. 

Feature | FFR Catheters| July 31, 2017 | Dave Fornell
The gold standard for assessing the hemodynamic significance or coronary lesions to determine if they should be revas
Siemens Healthineers to Acquire Epocal from Alere
News | Point of Care Testing| July 26, 2017
Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal...
New PET-CT Scan Improves Detection in Rare Cardiac Condition
News | PET-CT| July 25, 2017
Using a new imaging technique that can diagnose cardiac sarcoidosis much more accurately than traditional tests,...
3-D Vascular Ultrasound Quantifies Plaque Burden to Estimate Cardiovascular Risk
News | Cardiovascular Ultrasound| July 20, 2017
July 20, 2017 — In a large, first-of-its-kind population, researchers found an experimental technique known as...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG| July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Overlay Init